Short answer

Edgewise Therapeutics, Inc. (EWTX) filed its fiscal 2025 10-K annual report with the SEC on Feb 26, 2026.

Top risk flagged: FDA and EMA regulatory approval risks; lengthy, unpredictable processes may delay product commercialization

FY2025 key financial metrics · XBRL

Source: XBRL data from the Edgewise Therapeutics, Inc. (EWTX) FY2025 10-K on SEC EDGAR. USD.

AI summary of each section, grounded in the filing text

Core business: Discovery and development of precision small molecule therapies targeting severe skeletal and cardiac muscle diseases
New emphasis on sevasemten, an oral fast myosin inhibitor in late-stage trials for Duchenne and Becker muscular dystrophies with recent FDA Fast Track and Orphan Drug designations
Strategic focus shift to advancing muscle fiber stabilizing therapies with potential use as standalone or combination treatment, expanding clinical-stage muscular dystrophy and cardiac programs including EDG-7500 and EDG-15400
Pipeline growth with multiple clinical-stage assets and new preclinical candidates, including EDG-003 targeting cardiometabolic diseases
FDA approvals and setbacks in gene and exon skipping therapies for Duchenne highlight continued unmet need; Edgewise promotes mutation-agnostic, mechanistically novel approach potentially addressing broader patient populations

Net loss $167.8M in 2025 vs $133.8M in 2024, operating expenses rose $32.6M to $191.4M driven by R&D and G&A increases
R&D expenses $151.4M vs $127.0M (+19%), led by sevasemten $52.5M, EDG-7500 $18.4M, and new EDG-15400 $7.6M clinical program costs
General & admin expenses $40.0M vs $31.9M (+25.6%) due to higher personnel and professional fees
Cash from financing $196.1M in 2025 including $200M direct offering; cash used in operating activities $143.8M; cash and equivalents $530.1M at year-end
Management expects increasing expenses from advancing clinical trials, regulatory activities, and commercial preparation; risks include clinical trial outcomes, regulatory timing, capital needs, and macroeconomic uncertainties

FDA and EMA regulatory approval risks; lengthy, unpredictable processes may delay product commercialization
Macroeconomic risk from U.S. banking sector disruptions; Silicon Valley Bank failure may limit capital market access
Dependence on third-party manufacturers for sevasemten, EDG-7500, EDG-15400; supply disruptions could delay trials or commercialization
Competition risk from faster, safer, or cheaper products by unnamed competitors could reduce market opportunities
Financial risk: net loss $167.8M in 2025, accumulated deficit $546.4M; need for additional capital may dilute stockholders or restrict operations

Generated from the filing text; verify against the original. How to read a 10-K

Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.